News coverage about Sangamo Therapeutics (NASDAQ:SGMO) has trended somewhat positive recently, Accern reports. Accern scores the sentiment of media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Sangamo Therapeutics earned a media sentiment score of 0.17 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 45.0254640415856 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the news stories that may have impacted Accern Sentiment’s scoring:
Shares of Sangamo Therapeutics (NASDAQ SGMO) traded up $1.15 during mid-day trading on Friday, reaching $18.30. The company had a trading volume of 2,270,579 shares, compared to its average volume of 1,430,000. The stock has a market cap of $1,550.00, a price-to-earnings ratio of -26.52 and a beta of 3.15. Sangamo Therapeutics has a one year low of $3.35 and a one year high of $18.69. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.64 and a quick ratio of 5.64.
Sangamo Therapeutics (NASDAQ:SGMO) last announced its quarterly earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.19) by $0.04. Sangamo Therapeutics had a negative return on equity of 31.81% and a negative net margin of 157.66%. The firm had revenue of $11.81 million during the quarter, compared to analyst estimates of $10.37 million. During the same quarter in the previous year, the business earned ($0.27) EPS. Sangamo Therapeutics’s revenue for the quarter was up 333.0% compared to the same quarter last year. equities analysts predict that Sangamo Therapeutics will post -0.73 earnings per share for the current year.
SGMO has been the topic of several research reports. Wedbush reaffirmed a “hold” rating and set a $6.00 target price on shares of Sangamo Therapeutics in a research report on Wednesday, November 15th. BidaskClub cut Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday. Barclays began coverage on Sangamo Therapeutics in a research report on Wednesday, November 22nd. They set an “overweight” rating and a $20.00 target price on the stock. Zacks Investment Research cut Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, January 5th. Finally, Piper Jaffray Companies set a $25.00 price objective on Sangamo Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, January 3rd. Four equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $18.83.
In other Sangamo Therapeutics news, Director Saira Ramasastry sold 5,000 shares of the business’s stock in a transaction that occurred on Friday, November 17th. The stock was sold at an average price of $14.67, for a total value of $73,350.00. Following the sale, the director now owns 5,000 shares of the company’s stock, valued at $73,350. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Curt A. Herberts III sold 16,630 shares of the business’s stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $16.13, for a total value of $268,241.90. The disclosure for this sale can be found here. Over the last quarter, insiders sold 58,433 shares of company stock worth $979,696. 5.50% of the stock is currently owned by insiders.
COPYRIGHT VIOLATION WARNING: “Sangamo Therapeutics (SGMO) Getting Somewhat Positive Media Coverage, Report Shows” was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this piece of content can be read at https://www.dispatchtribunal.com/2018/01/13/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-sangamo-therapeutics-sgmo-stock-price.html.
Sangamo Therapeutics Company Profile
Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.